TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Subscribe to see TransMedics Group, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
TransMedics Group, Inc. is a medical devices company headquartered in Andover, United States. It is publicly listed (TMDX) with a market capitalisation of $2.7B. Xcout tracks 23 named people at TransMedics Group, Inc., including Fernando Araujo (Chief Financial Officer & Treasurer). Xcout recorded 56 job postings from TransMedics Group, Inc. in the last 90 days, naming tools such as Jira, Workday.
17 more named people on record for TransMedics Group, Inc., with roles, board committees and tenure — see the full roster →
Xcout recorded 56 job postings from TransMedics Group, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see TransMedics Group, Inc.'s hiring signals →
A few of TransMedics Group, Inc.'s closest competitors — see the full list of competitors and alternatives →
Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothenburg, Sweden, the company extends its operations across Sweden, the United States, the broader regions of North and South America, Europe, the Middle East, Africa, and the Asia Pacific. Their product line encompasses the XVIVO System (XPS), an integrated, off-the-shelf cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). Accompanying this is the XPS Disposable Lung Kit, supplying necessary sterile disposables and pre-packaged components. They also provide STEEN Solution, a uniquely formulated buffered extracellular solution optimized for perfusing isolated donor lungs during EVLP, and Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution for organ preservation. Additional offerings include the XVIVO Silicone Tubing Set for efficient flushing of donor lungs during procurement, as well as the XVIVO LS and XVIVO Disposable Lung Set, which together constitute a dedicated EVLP device. Furthermore, Xvivo Perfusion supplies the XVIVO Organ Chamber, a single-use sterile disposable container designed as a temporary holding unit for isolated lungs before transplantation, alongside the single-use, sterile XVIVO Lung Cannula Set.
OrganOx is an organ technology company founded as a spin-out from the University of Oxford, United Kingdom. It pioneers liver perfusion technology to address transplant challenges and improve transplant success through innovation and clinical research.
Bridge to Life Ltd. provides organ preservation solutions and proven medical technologies. Headquartered in Duluth, Georgia, the privately held company also maintains European operations.
ALung Technologies, Inc. is a leading provider of low-flow extracorporeal carbon dioxide removal technologies. The company was acquired by LivaNova in May 2022. It focuses on advancing respiratory care solutions.
BioVentrix, Inc. is a privately held specialty medical device company headquartered in Mansfield, Massachusetts. The firm serves cardiothoracic surgeons and patients by developing lifesaving therapies for heart failure.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.